Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Previous studies have shown that the FGF signaling pathway is closely related to endocrine
therapy resistance in breast cancer, but there is not sufficient evidence for the combination
of endocrine therapy and FGFR inhibitors. Anlotinib is a highly effective VEGFRs, FGFRs,
PDGFRs multi-target tyrosine kinase inhibitor. Therefore, we conducted this single-arm,
single-center phase II clinical study to evaluate the efficacy and the safety of anlotinib
combined with fulvestrant in patients with metastatic HR+/HER2- breast cancer patients with
FGFR mutation and resistance to aromatase inhibitor therapy, to provide new treatment options
for these patients.